BACKGROUND: Deaths during induction chemotherapy for pediatric acute lymphoblastic leukemia (ALL) account for one-tenth of ALL-associated mortality and half of ALL treatment-related mortality. We sought to ascertain patient- and hospital-level factors associated with induction mortality. PROCEDURE: We performed a retrospective cohort analysis of 8,516 children ages 0 to <19 years with newly diagnosed ALL admitted to freestanding US children's hospitals from 1999 to 2009 using the Pediatric Health Information System database. Induction mortality risk was modeled accounting for demographics, intensive care unit-level interventions, and socioeconomic status (SES) using Cox regression. The association of ALL induction mortality with hospital-level factors including volume, hospital-wide mortality and payer mix was analyzed with multiple linear regression. RESULTS: ALL induction mortality was 1.12%. Race and patient-level SES factors were not associated with induction mortality. Patients receiving both mechanical ventilation and vasoactive infusions experienced nearly 50% mortality (hazard ratio 122.30, 95% CI 66.56-224.80). Institutions in the highest induction mortality quartile contributed 27% of all patients but nearly half of all deaths (47 of 95). Hospital payer mix was associated with ALL induction mortality after adjustment for other hospital-level factors (P = 0.046). CONCLUSIONS: The overall risk of induction death is low but substantially increased in patients with cardio-respiratory and other organ failures. Induction mortality varies up to three-fold across hospitals and is correlated with hospital payer mix. Further work is needed to improve induction outcomes in hospitals with higher mortality. These data suggest an induction mortality rate of less than 1% may be an attainable national benchmark.
BACKGROUND: Deaths during induction chemotherapy for pediatric acute lymphoblastic leukemia (ALL) account for one-tenth of ALL-associated mortality and half of ALL treatment-related mortality. We sought to ascertain patient- and hospital-level factors associated with induction mortality. PROCEDURE: We performed a retrospective cohort analysis of 8,516 children ages 0 to <19 years with newly diagnosed ALL admitted to freestanding US children's hospitals from 1999 to 2009 using the Pediatric Health Information System database. Induction mortality risk was modeled accounting for demographics, intensive care unit-level interventions, and socioeconomic status (SES) using Cox regression. The association of ALL induction mortality with hospital-level factors including volume, hospital-wide mortality and payer mix was analyzed with multiple linear regression. RESULTS: ALL induction mortality was 1.12%. Race and patient-level SES factors were not associated with induction mortality. Patients receiving both mechanical ventilation and vasoactive infusions experienced nearly 50% mortality (hazard ratio 122.30, 95% CI 66.56-224.80). Institutions in the highest induction mortality quartile contributed 27% of all patients but nearly half of all deaths (47 of 95). Hospital payer mix was associated with ALL induction mortality after adjustment for other hospital-level factors (P = 0.046). CONCLUSIONS: The overall risk of induction death is low but substantially increased in patients with cardio-respiratory and other organ failures. Induction mortality varies up to three-fold across hospitals and is correlated with hospital payer mix. Further work is needed to improve induction outcomes in hospitals with higher mortality. These data suggest an induction mortality rate of less than 1% may be an attainable national benchmark.
Authors: Scott P Narus; Rajendu Srivastava; Ramkiran Gouripeddi; Oren E Livne; Peter Mo; Jonathan P Bickel; David de Regt; Joseph W Hales; Eric Kirkendall; Richard L Stepanek; Jamie Toth; Ron Keren Journal: AMIA Annu Symp Proc Date: 2011-10-22
Authors: Marko Kavcic; Brian T Fisher; Yimei Li; Alix E Seif; Kari Torp; Dana M Walker; Yuan-Shung Huang; Grace E Lee; Sarah K Tasian; Marijana Vujkovic; Rochelle Bagatell; Richard Aplenc Journal: Cancer Date: 2013-02-21 Impact factor: 6.860
Authors: R Aplenc; B T Fisher; Y S Huang; Y Li; T A Alonzo; R B Gerbing; M Hall; D Bertoch; R Keren; A E Seif; L Sung; P C Adamson; A Gamis Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890
Authors: Brian T Fisher; Tracey Harris; Kari Torp; Alix E Seif; Ami Shah; Yuan-Shung V Huang; L Charles Bailey; Leslie S Kersun; Anne F Reilly; Susan R Rheingold; Dana Walker; Yimei Li; Richard Aplenc Journal: Med Care Date: 2014-01 Impact factor: 2.983
Authors: Jeffrey D Colvin; Isabella Zaniletti; Evan S Fieldston; Laura M Gottlieb; Jean L Raphael; Matthew Hall; John D Cowden; Samir S Shah Journal: Pediatrics Date: 2012-12-17 Impact factor: 7.124
Authors: Jeffrey E Rubnitz; Shelly Lensing; Yinmei Zhou; John T Sandlund; Bassem I Razzouk; Raul C Ribeiro; Ching-Hon Pui Journal: Cancer Date: 2004-10-01 Impact factor: 6.860
Authors: Jennifer J Wilkes; Sean Hennessy; Rui Xiao; Susan Rheingold; Alix E Seif; Yuan-Shung Huang; Neika Vendetti; Yimei Li; Rochelle Bagatell; Richard Aplenc; Brian T Fisher Journal: Clin Lymphoma Myeloma Leuk Date: 2016-05-04
Authors: Julie C Fitzgerald; Yimei Li; Brian T Fisher; Yuan-Shung Huang; Tamara P Miller; Rochelle Bagatell; Alix E Seif; Richard Aplenc; Neal J Thomas Journal: Pediatr Crit Care Med Date: 2018-06 Impact factor: 3.624
Authors: Azada Ibrahimova; Lena E Winestone; Tamara P Miller; Kyle Kettler; Alix E Seif; Yuan-Shung Huang; Caitlin W Elgarten; Regina M Myers; Brian T Fisher; Richard Aplenc; Kelly D Getz Journal: Pediatr Blood Cancer Date: 2021-03-11 Impact factor: 3.167
Authors: Hanna Mogensen; Karin Modig; Giorgio Tettamanti; Friederike Erdmann; Mats Heyman; Maria Feychting Journal: Front Oncol Date: 2018-10-31 Impact factor: 6.244